Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.66 |
| ▸ | MET | P08581 | 4/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263594 | 0.88 | TTR (0.64) | APPMETTTRDPP4FDPS | |
| SCHEMBL2233161 | 0.85 | APP (0.80) | APPMETTTRDPP4ESR1 | |
| SCHEMBL12190733 | 0.84 | APP (0.62) | APPMETTTRDPP4ESR1 | |
| SCHEMBL19359031 | 0.83 | APP (0.72) | APPTTRDPP4FDPSCA12 | |
| SCHEMBL19359027 | 0.83 | APP (0.72) | APPTTRDPP4FDPSCA12 | |
| SCHEMBL12173624 | 0.82 | APP (0.66) | APPMETESR1ATMCA12 | |
| SCHEMBL28884853 | 0.82 | APP (0.68) | APPTTRDPP4ESR1FDPS | |
| SCHEMBL14727949 | 0.81 | APP (0.81) | APPMETTTRDPP4ESR1 | |
| SCHEMBL6794960 | 0.80 | APP (0.68) | APPTTRDPP4ESR1ATM | |
| SCHEMBL6794964 | 0.80 | APP (0.68) | APPTTRDPP4ESR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | IL36G, IL17A, IL6ST | APP 4845/4885MET 1177/4885TTR 1215/4885 |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | SLC10A1, HAVCR2, GOT2 | APP 4881/4885MET 153/4885TTR 503/4885 |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | SLC10A1, HAVCR2, ABL1 | APP 4849/4885MET 167/4885TTR 867/4885 |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | APP 4875/4885MET 177/4885TTR 991/4885 |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | APP 4829/4885MET 935/4885TTR 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.